ArticleThe pharmacogenomics journal2017
Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies.
Article in The pharmacogenomics journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines.Frontiers in pharmacology · 2020Pooled it
- Model-based clinical utility of pharmacogenetic testing and its potential population impact on the use of essential medicines in Zimbabwe.Frontiers in pharmacology · 2026Article
- Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test.Clinical pharmacology and therapeutics · 2025Review
- Article
- Pharmacogenomic implications of the differential distribution of CYP2C9 metabolic phenotypes among Latin American populations.Frontiers in pharmacology · 2023Article
- Polypharmacy and precision medicine.Cambridge prisms. Precision medicine · 2023Review
- Barriers to genetic testing in clinical psychiatry and ways to overcome them: from clinicians' attitudes to sociocultural differences between patients across the globe.Translational psychiatry · 2022Review
- Clinical Impact of Functional CYP2C19 and CYP2D6 Gene Variants on Treatment with Antidepressants in Young People with Depression: A Danish Cohort Study.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Review
- Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies.Frontiers in neurology · 2022Article
- Genotyping for HLA risk alleles versus patch tests to diagnose anti-seizure medication induced cutaneous adverse drug reactions.Frontiers in pharmacology · 2022Article
- Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study.Journal of personalized medicine · 2021Article
- HLA-associated adverse drug reactions - scoping review.Clinical and translational science · 2021Article
- Interplay between IL6 and CRIM1 in thiopurine intolerance due to hematological toxicity in leukemic patients with wild-type NUDT15 and TPMT.Scientific reports · 2021Article
- Population impact of pharmacogenetic tests in admixed populations across the Americas.The pharmacogenomics journal · 2021Article
- Genetic Susceptibility Toward Nausea and Vomiting in Surgical Patients.Frontiers in genetics · 2021Article
- Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon.Pharmacogenomics and personalized medicine · 2021Article
- HLA associations with infliximab-induced liver injury.The pharmacogenomics journal · 2020Article
- Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease.Alimentary pharmacology & therapeutics · 2020Article
- Implementation of Pharmacogenetics in Primary Care: A Multi-Stakeholder Perspective.Frontiers in genetics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
Abstract
The progressing discovery of genetic variants associated with drug-related adverse events has raised expectations for pharmacogenetic tests to improve drug efficacy and safety. To further the use of pharmacogenetics in health care, tests with sufficient potential to improve efficacy and safety, as reflected by good clinical validity and population impact, need to be identified. The potential benefit of pharmacogenetic tests is often concluded from the strength of the association between the variant and the adverse event; measures of clinical validity are generally not reported. This paper describes measures of clinical validity and potential population health impact that can be calculated from association studies. We explain how these measures are influenced by the strength of the association and by the frequencies of the variant and the adverse event. The measures are illustrated using examples of testing for HLA-B*5701 associated with abacavir-induced hypersensitivity and SLCO1B1 c.521T>C (*5) associated with simvastatin-induced adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.